Form 10-Q
GILEAD SCIENCES INC filed this Form 10-Q on 08/06/2018
Document Outline
Entire Document (7241.8 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - GILEAD SCIENCES, INC.
Page 3 - GILEAD SCIENCES, INC.
Page 4 - GILEAD SCIENCES, INC.
Page 5 - GILEAD SCIENCES, INC.
Page 6 - GILEAD SCIENCES, INC.
Page 7 - GILEAD SCIENCES, INC.
Page 8 - Recently Issued Accounting Pronouncements Not Yet Adopted
Page 9 - Product Sales
Page 10 - Revenue Recognized from Performance Obligations Satisfied in Prior Periods
Page 11 - N/A
Page 12 - N/A
Page 13 - Level 2 Inputs
Page 14 - N/A
Page 15 - N/A
Page 16 - Acquisition
Page 17 - Collaborations and Other Arrangements
Page 18 - Other Accrued Liabilities
Page 19 - N/A
Page 20 - Litigation Related to Sofosbuvir
Page 21 - Litigation with Merck
Page 22 - Petitions for Inter Partes Review filed by Initiative for Medicines, Access Knowledge
Page 23 - Litigation Related to Bictegravir
Page 24 - HCV Products
Page 25 - Other Matters
Page 26 - Stock Repurchase Program
Page 27 - Altera Corp. v. Commissioner
Page 28 - RESULTS OF OPERATIONS
Page 29 - HIV and Liver Diseases Programs
Page 30 - Financial Highlights
Page 31 - Product sales for the six months ended June 30, 2018
Page 32 - N/A
Page 33 - N/A
Page 34 - Cost of Goods Sold and Product Gross Margin
Page 35 - Selling, General and Administrative Expenses
Page 36 - Liquidity and Capital Resources
Page 37 - Critical Accounting Policies, Estimates and Judgments
Page 38 - Recent Accounting Pronouncements
Page 39 - In evaluating our business, you should carefully consider the following risks in addition to the oth
Page 40 - If we fail to commercialize new products or expand the indications for existing products, our prospe
Page 41 - Yescarta, a chimeric antigen receptor (CAR) T cell therapy, represents a novel approach to cancer tr
Page 42 - Our results of operations may be adversely affected by current and potential future healthcare refor
Page 43 - Laws and regulations applicable to the health care industry could impose new obligations on us, requ
Page 44 - Our operations depend on compliance with complex FDA and comparable international regulations. Failu
Page 45 - Due to our reliance on third-party contract research organizations to conduct our clinical trials, w
Page 46 - Our success depends to a significant degree on our ability to defend our patents and other intellect
Page 47 - Our success depends in large part on our ability to operate without infringing upon the patents or o
Page 48 - Litigation with the University of Minnesota
Page 49 - If any party is successful in establishing exclusive rights to axicabtagene ciloleucel, our anticipa
Page 50 - We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufa
Page 51 - Litigation with generic manufacturers has increased our expenses which may continue to reduce our ea
Page 52 - Imports from countries where our products are available at lower prices and unapproved generic or co
Page 53 - In some countries, governments may grant compulsory licenses for our products or our patents may not
Page 54 - We are dependent on information technology systems, infrastructure and data.
Page 55 - USE OF PROCEEDS
Page 56 - Exhibit Index
Page 57 - N/A
Page 58 - N/A
Page 59 - SIGNATURES
Subdocument 2 - EX-10.26 - EXHIBIT 10.26
Page 1 - Exhibit 10.26
Page 2 - i.e.,
Page 3 - N/A
Page 4 - Paying Entity
Page 5 - Questions
Subdocument 3 - EX-31.1 - CEO CERTIFICATION
Page 1 - N/A
Subdocument 4 - EX-31.2 - CFO CERTIFICATION
Page 1 - N/A
Subdocument 5 - EX-32.1 - SECTION 906 CERTIFICATIONS
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT (What's this?)
XBRL Viewer
NASDAQ (US Dollar)
$71.67
 Stock is Down 0.67 (0.93%)
Data as of 10/23/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Gilead Sciences at the Morgan Stanley 16th Annual Global Healthcare Conference

September 12, 2018 11:05 a.m. ET
Play
Second Quarter 2018 Gilead Sciences Earnings Conference Call

July 25, 2018 2:00 p.m. PT
Play
Gilead Sciences at the Goldman Sachs 39th Annual Global Healthcare Conference

June 13, 2018 8:40 a.m. PT
Play
Gilead Sciences at Jefferies 2018 Global Healthcare Conference

June 06, 2018 10:30 a.m. ET
Play